Dr. Yardley on Integrating Biosimilars Into Breast Cancer Treatment

Denise Yardley, MD
Published: Tuesday, Oct 01, 2019



Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the impact of biosimilars on breast cancer treatment.

As more biosimilars receive approval for use in breast cancer treatment, physicians must become comfortable with using them in practice and institutions must create policies, explains Yardley. The presence of more biosimilars increases financial advantages and potentially increases opportunities for patients, according to Yardley.

However, some questions still remain with biosimilars, including whether they are a complete substitution of the original drug and if there are caveats to using biosimilars, says Yardley. The oncology community must learn how to integrate them into practice, Yardley concludes.
SELECTED
LANGUAGE


Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the impact of biosimilars on breast cancer treatment.

As more biosimilars receive approval for use in breast cancer treatment, physicians must become comfortable with using them in practice and institutions must create policies, explains Yardley. The presence of more biosimilars increases financial advantages and potentially increases opportunities for patients, according to Yardley.

However, some questions still remain with biosimilars, including whether they are a complete substitution of the original drug and if there are caveats to using biosimilars, says Yardley. The oncology community must learn how to integrate them into practice, Yardley concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Community Practice Connections™: Show Me the Data™: Leveraging the Evidence to Optimize Applications of Biosimilars in CancerAug 30, 20201.5
Publication Bottom Border
Border Publication
x